- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CAV1/ BSCL3/ CGL3 monoclonal antibody
Anti-CAV1/ BSCL3/ CGL3 antibody for FACS & in-vivo assay
Go to CAV1/CAV1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T93945-Ab-1/ GM-Tg-hg-T93945-Ab-2 | Anti-Human CAV1 monoclonal antibody | Human |
| GM-Tg-rg-T93945-Ab-1/ GM-Tg-rg-T93945-Ab-2 | Anti-Rat CAV1 monoclonal antibody | Rat |
| GM-Tg-mg-T93945-Ab-1/ GM-Tg-mg-T93945-Ab-2 | Anti-Mouse CAV1 monoclonal antibody | Mouse |
| GM-Tg-cynog-T93945-Ab-1/ GM-Tg-cynog-T93945-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CAV1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T93945-Ab-1/ GM-Tg-felg-T93945-Ab-2 | Anti-Feline CAV1 monoclonal antibody | Feline |
| GM-Tg-cang-T93945-Ab-1/ GM-Tg-cang-T93945-Ab-2 | Anti-Canine CAV1 monoclonal antibody | Canine |
| GM-Tg-bovg-T93945-Ab-1/ GM-Tg-bovg-T93945-Ab-2 | Anti-Bovine CAV1 monoclonal antibody | Bovine |
| GM-Tg-equg-T93945-Ab-1/ GM-Tg-equg-T93945-Ab-2 | Anti-Equine CAV1 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T93945-Ab-1/ GM-Tg-hg-T93945-Ab-2; GM-Tg-rg-T93945-Ab-1/ GM-Tg-rg-T93945-Ab-2; GM-Tg-mg-T93945-Ab-1/ GM-Tg-mg-T93945-Ab-2; GM-Tg-cynog-T93945-Ab-1/ GM-Tg-cynog-T93945-Ab-2; GM-Tg-felg-T93945-Ab-1/ GM-Tg-felg-T93945-Ab-2; GM-Tg-cang-T93945-Ab-1/ GM-Tg-cang-T93945-Ab-2; GM-Tg-bovg-T93945-Ab-1/ GM-Tg-bovg-T93945-Ab-2; GM-Tg-equg-T93945-Ab-1/ GM-Tg-equg-T93945-Ab-2 |
| Products Name | Anti-CAV1 monoclonal antibody |
| Format | mab |
| Target Name | CAV1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CAV1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species CAV1/ BSCL3/ CGL3 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLV000315 | human CAV1 Lentivirus particle |
| ORF Viral Vector | vGMAP000101 | Human CAV1 Adenovirus particle |
| ORF Viral Vector | pGMLV000316 | human CAV1 Lentivirus plasmid |
| ORF Viral Vector | pGMAP000101 | Human CAV1 Adenovirus plasmid |
| ORF Viral Vector | vGMLV000316 | human CAV1 Lentivirus particle |
| ORF Viral Vector | pGMLV000315 | human CAV1 Lentivirus plasmid |
| ORF Viral Vector | pGMLV000808 | Norway rat Cav1 Lentivirus plasmid |
| ORF Viral Vector | pGMAAV000143 | mouse Cav1 AAV plasmid |
| ORF Viral Vector | vGMLV000808 | Norway rat Cav1 Lentivirus particle |
| ORF Viral Vector | vGMAAV000143 | mouse Cav1 AAV particle |
| ORF Viral Vector | pGMLV000592 | naked mole-rat CAV-1 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000592 | naked mole-rat CAV-1 Lentivirus particle |
Target information
| Target ID | GM-T93945 |
| Target Name | CAV1 |
| Gene ID | 857,12389,25404,704449,403980,493668,281040,100055975 |
| Gene Symbol and Synonyms | BSCL3,Cav,Cav-1,CAV1,Caveolin-1,CGL3,LCCNS,MSTP085,PPH3,VIP21 |
| Uniprot Accession | Q03135,P41350,P33724,A0M8S7,P79132,Q2QLB0 |
| Uniprot Entry Name | CAV1_HUMAN,CAV1_RAT,CAV1_FELCA,CAV1_CANLF,CAV1_BOVIN,CAV1_HORSE |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target |
| Disease | Prostate Cancer |
| Gene Ensembl | ENSG00000105974 |
| Target Classification | N/A |
The target: CAV1, gene name: CAV1, also named as BSCL3, CGL3, LCCNS, MSTP085, PPH3, VIP21. The scaffolding protein encoded by this gene is the main component of the caveolae plasma membranes found in most cell types. The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression. The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 mitogen-activated kinase cascade. Caveolin 1 and caveolin 2 are located next to each other on chromosome 7 and express colocalizing proteins that form a stable hetero-oligomeric complex. Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy. Alternatively spliced transcripts encode alpha and beta isoforms of caveolin 1.[provided by RefSeq, Mar 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
